摘要
目的:系统评价银杏叶制剂联合尼可地尔治疗冠心病心绞痛的有效性与安全性.方法:检索国家知识基础设施数据库(CNKI)、中国生物医学文献数据库(CBM)、万方数据知识服务平台(Wanfang)、维普中文科技期刊全文数据库(VIP)、PubMed、the Cochrane Library、Embase等数据库,时间范围为建库至2022年10月.收集银杏叶制剂联合尼可地尔治疗冠心病心绞痛的随机对照试验(RCTs)、队列研究.应用Revman 5.4.1软件进行Meta分析,Stata 16.0软件进行发表偏倚分析.结果:共纳入10项研究,包括1167名患者.Meta分析结果显示:与对照组相比,试验组总有效率(OR=3.87,95％CI 2.59～5.78,P＜0.001)显著升高,心绞痛发作次数(MD=-2.28,95％CI-2.66～-1.90,P＜0.001)、心绞痛持续时间(MD=-1.65,95％CI-2.12～-1.18,P＜0.001)、硝酸甘油用量(SMD=-2.89,95％CI-3.15～-2.62,P＜0.001)、不良反应发生率(OR=0.40,95％CI 0.24～0.66,P＜0.001)显著降低.结论:银杏叶制剂联合尼可地尔治疗冠心病心绞痛的有效性及安全性均显著优于尼可地尔单药及常规西药治疗.
Abstract
Objective:To systematically evaluate the effectiveness and safety of ginkgo biloba preparation combined with nicorandil in the treatment of angina pectoris of coronary heart disease.Methods:We searched CNKI,CBM,Wanfang,VIP,PubMed,the Cochrane Library and Embase for randomized controlled trials(RCTs)and cohort studies comparing the effectiveness and safety upon angina pectoris of coronary heart disease between ginkgo biloba preparation combined with nicorandil versus standard therapy or nicorandil monotherapy before October 2022.Revman 5.4.1 software was used to perform meta-analysis,while Stata 16.0 software was applied to conduct publication bias analysis.Results:A total of 10 studies were enrolled,including 1167 patients.Meta-analysis re-sults showed that compared with those in control group,patients in trial group had significant higher total effective rate(OR=3.87,95％CI 2.59～5.78,P＜0.001),and significant lower angina frequency(MD=-2.28,95％CI-2.66～-1.90,P＜0.001),angina duration(MD=-1.65,95％CI-2.12～-1.18,P＜0.001),nitroglycerin dosage(SMD=-2.89,95％CI-3.15～-2.62,P＜0.001)and incidence of adverse reactions(OR=0.40,95％CI0.24～0.66,P＜0.001).Conclusion:Ginkgo biloba preparation combined with nicorandil are more effective and safer than nicorandil monotherapy and conventional western medicine in the treatment of angina pectoris of cor-onary heart disease.
维普
万方数据